ORAGENICS INC (OGEN)
AMEXHealth CareBiotechnologySnapshot 2026-11-04
$0.37+0.51%
Close 2026-11-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · OGEN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -63.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
OGEN — legal / regulatory event — NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDAR…
Dated 2026-08-28
NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING. On August 26, 2026, Oragenics, Inc. (the “ Company ”) received notification (the “ Notice ”) from the NYSE American LLC (the “ NYSE American ”) that the Company is no longer in compliance with NYSE American’s continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii)…
Why it matters: OGEN is below two exchange equity rules. A rejected or late plan could put its listing at risk.
Worry ifNYSE American accepts OGEN's plan to regain compliance. The company submits it within 45 days of August 26, 2026.
Less concerning ifOGEN misses the 45-day deadline, or NYSE American rejects the plan.
Why it matters: The filing is a key step toward planned U.S. Phase IIb trials. A delay would push back that path.
Supportive ifOragenics files an ONP-002 IND with the FDA by December 31, 2026.
Worry ifOragenics does not file by December 31, 2026, or reports a delay or FDA hold.
Why it matters: The May letter of intent is non-binding. A final deal would make the proposed second TBI treatment program more concrete.
Supportive ifOragenics and Sigyn sign a final license deal for CardioDialysis. The deal covers treatment of TBI or other named conditions.
Worry ifThe parties say talks have ended, or they do not sign a final deal after the stated 90-day target.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$186 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $798 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,845 loss on $10,000 · 68.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.